Ligand Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $47,627 | $45,333 | $42,812 | $51,812 |
Gross Profit | 36,462 | 40,484 | 39,975 | 39,317 |
EBITDA | 9,720 | -40,543 | -29,690 | 3,396 |
EBIT | 1,625 | -49,313 | -38,317 | -5,598 |
Net Income | 4,847 | -42,451 | -31,088 | -7,172 |
Net Change In Cash | 47,627 | 45,333 | 42,812 | 51,812 |
Free Cash Flow | 15,585 | -25,659 | 27,759 | 22,289 |
Cash | 245,020 | 47,989 | 72,307 | 63,619 |
Basic Shares | 19,259 | 19,191 | 18,974 | 18,419 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $167,133 | $131,314 | $196,245 | $277,133 |
Gross Profit | 156,059 | 96,265 | 143,418 | 214,957 |
EBITDA | 40,794 | 100,837 | 81,204 | 133,161 |
EBIT | 5,555 | 64,316 | 37,810 | 91,824 |
Net Income | -4,032 | 52,154 | -33,361 | 57,138 |
Net Change In Cash | 167,133 | 131,314 | 196,245 | 277,133 |
Cost of Revenue | -28,440 | |||
Free Cash Flow | 95,226 | 46,056 | 119,927 | 70,037 |
Cash | 72,307 | 22,954 | 45,006 | 19,522 |
Basic Shares | 18,290 | 17,757 | 16,868 | 17,246 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | $1.60 |
2025-03-31 | $1.33 |
2024-12-31 | $1.27 |
